Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 1.69B +287.3% |
| Revenue (ttm) | n/a |
| Net Income | -150.11M |
| EPS | -1.49 |
| Shares Out | 111.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,452,057 |
| Open | 15.98 |
| Previous Close | 16.06 |
| Day's Range | 14.70 - 15.98 |
| 52-Week Range | 4.20 - 18.61 |
| Beta | -0.10 |
| Analysts | Strong Buy |
| Price Target | 23.00 (+51.32%) |
| Earnings Date | May 7, 2026 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $23.0, which is an increase of 51.32% from the latest price.
News
Amylyx sees cash runway into 2028
Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, compared to $317.0 million at December 31, 2025. Based on its current operating plans, Amylyx (AMLX) expects
Amylyx Pharmaceuticals Earnings Call Transcript: Q1 2026
Advanced pivotal phase III LUCIDITY trial for avexitide in PBH, with top-line data expected next quarter and commercial launch preparations underway. Ended Q1 with $279.8M in cash, supporting a runway into 2028. Expanded access program launched to address urgent patient need.
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.
Amylyx announces launch of U.S. EAP for adults with PBH
Amylyx (AMLX) Pharmaceuticals announced the launch of a U.S. Expanded Access Program, EAP, for up to 250 adults with post-bariatric hypoglycemia, PBH, to provide treatment access to avexitide, an inve...
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with ...
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026.
Amylyx price target raised to $21 from $19 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $21 from $19 and keeps an Outperform rating on the shares ahead of the Q1 report. The
Amylyx Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
Avexitide, a GLP-1 antagonist for post-bariatric hypoglycemia, is in phase III trials with results expected in Q3 2025. Prior studies showed a 64% reduction in severe hypoglycemic events, and the company is targeting a 2027 launch for this first-in-class therapy.
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
Amylyx (AMLX) Pharmaceuticals announced that the last participant has been randomized and dosed in the Phase 3 Lucidity clinical trial of avexitide. Lucidity is a 16-week, multicenter, randomized, dou...
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.
Amylyx price target raised to $30 from $25 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Amylyx (AMLX) to $30 from $25 and keeps a Buy rating on the shares based on “high confidence” in a
Amylyx Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Avexitide, a GLP-1 receptor antagonist, is in a pivotal phase III trial for post-bariatric hypoglycemia, with prior studies showing strong efficacy and FDA breakthrough designation. Market research confirms a large orphan population, and future plans include label expansion and a long-acting formulation.
Amylyx price target raised to $34 from $28 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Amylyx (AMLX) to $34 from $28 and keeps a Buy rating on the shares. Following recent engagement with institutional
Amylyx Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Top-line results from the pivotal avexitide phase III trial in PBH are expected in Q3 2026, with NDA submission and commercialization targeted for 2027. The pipeline includes ALS and Wolfram syndrome programs, and a long-acting GLP-1 antagonist is in early development.
Amylyx files automatic mixed securities shelf
08:07 EST Amylyx (AMLX) files automatic mixed securities shelf
Amylyx Pharmaceuticals Earnings Call Transcript: Q4 2025
Advanced pipeline and completed LUCIDITY Phase III trial recruitment for Avexitide, with top-line data expected Q3 2026 and a strong cash position extending runway into 2028. Commercial launch preparations and expanded pipeline efforts continue amid significant unmet need in PBH.
Amylyx reports Q4 EPS (30c), consensus (34c)
“2025 was a year of meaningful advancement for Amylyx’s (AMLX) pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,” said Joshua Cohen and Justin ...
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the fourth quarter and full year ended Dece...
Amylyx initiated with a Buy at Stifel
Stifel initiated coverage of Amylyx (AMLX) with a Buy rating and $21 price target The firm thinks avexitide’s Phase 3 study likely works, pinning 75% odds of success on that
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences.
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026.
Amylyx price target raised to $19 from $15 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Amylyx (AMLX) to $19 from $15 and keeps a Buy rating on the shares. The firm’s raised target reflects its